綠康生化(002868.SZ):擬註銷全資子公司綠康香港
格隆匯 8 月 28日丨綠康生化(002868.SZ)公告,公司於2020年8月28日召開第三屆董事會第十九次會議審議通過了《關於註銷全資子公司的議案》,同意註銷綠康香港有限公司(以下簡稱“綠康香港”)。根據《深圳證券交易所股票上市規則》及《公司章程》等相關規定,本次註銷事項在董事會決策權限範圍內,無需提交公司股東大會審議,本次註銷事項不涉及關聯交易,也不構成重大資產重組。
本次註銷全資子公司有利於優化公司業務結構和資源配置,降低管理成本,提高運營效率。綠康香港本次註銷完成後,將不再納入公司合併財務報表範圍,不會對公司整體業務發展和盈利水平產生重大不利影響,不存在損害公司及全體股東、特別是中小股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.